289 related articles for article (PubMed ID: 11109640)
1. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].
De Graeve D; Verhaegen J; Ament A; Baltussen R
Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
[TBL] [Abstract][Full Text] [Related]
3. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
Ortqvist A; Jönsson B; Baltussen R; Ament A
Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium.
De Graeve D; Lombaert G; Goossens H
Pharmacoeconomics; 2000 Jun; 17(6):591-601. PubMed ID: 10977396
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.
Sisk JE; Moskowitz AJ; Whang W; Lin JD; Fedson DS; McBean AM; Plouffe JF; Cetron MS; Butler JC
JAMA; 1997 Oct 22-29; 278(16):1333-9. PubMed ID: 9343464
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
11. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
Postma MJ; Heijnen ML; Beutels P; Jager JC
Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.
Jiang Y; Yang X; Taniguchi K; Petigara T; Abe M
J Med Econ; 2018 Jul; 21(7):687-697. PubMed ID: 29723081
[TBL] [Abstract][Full Text] [Related]
15. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
[TBL] [Abstract][Full Text] [Related]
16. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).
Díez-Domingo J; Ridao-López M; Gutiérrez-Gimeno MV; Puig-Barberá J; Lluch-Rodrigo JA; Pastor-Villalba E
Vaccine; 2011 Dec; 29(52):9640-8. PubMed ID: 22027484
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland.
Ess SM; Schaad UB; Gervaix A; Pinösch S; Szucs TD
Vaccine; 2003 Jul; 21(23):3273-81. PubMed ID: 12804858
[TBL] [Abstract][Full Text] [Related]
20. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
